FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953214030> ?p ?o ?g. }

• W2953214030 abstract "7028 Background: Inhibition of cholesterol synthesis and uptake sensitizes AML blasts to chemotherapy (Blood 104: 1816, 2004). A prior Phase 1 study demonstrated the safety of high dose pravastatin given with idarubicin and cytarabine in patients with AML and also reported an encouraging response rate (Blood 109: 2999, 2007). SWOG S0919 therefore evaluated the complete remission (CR) rate in a larger number of pts with relapsed AML treated with the pravastatin dose arrived at in the Phase 1 trial. Methods: Pts were treated at SWOG institutions from Aug 2009 through Nov 2012. Pravastatin was supplied by Bristol-Meyers Squibb. The protocol was approved by each institution’s review board. Eligibility: age ≥ 18 yrs, relapsed AML, cardiac ejection fraction ≥ 45%, CR/ CR with incomplete count recovery (CRi) following most recent chemotherapy lasting ≥ 3 months, no prior hematopoietic cell transplant. Treatment: oral pravastatin 1280 mg Days 1-8, idarubicin 12 mg/m 2 /d IV Days 4-6, and cytarabine 1.5 g/m 2 /d continuous IV infusion Days 4-7. Pts achieving a CR could receive 2 cycles of consolidation. CR and CRi were defined by IWG criteria. Fifty eligible pts were to be accrued. If ≥ 21 pts achieved CR or CRi, the regimen would be considered sufficiently effective (critical level = 4.8% if true CR rate = 30% and power of 90% if true CR rate = 50%). Results: The study closed to accrual on Nov 1, 2012 after meeting the defined criterion for a positive study. Thirty-six pts with a median age of 59 yr (range 23-78) were enrolled. Seventeen pts (47%) were male and the median WBC was 2800/ uL (range 700-110,600). The median time from initial dx to registration was 18 mo (range 5-136). Relapse status: 1 st : 17 pts (47%), 2 nd : 15 (42%), 3 rd : 2 (5.5%), and 4 th : 2 (5.5%). Eighteen pts have died, 3 during treatment. The response rate was 75% (95% CI 58-88%; 20 CR, 7 CRi); and the median overall survival was 10 mo. The p-value comparing 75% to 30% (null response rate) is 3.356 x 10 -8 . Duration of last CR (≤ 6 months) and prior high dose cytarabine exposure did not affect response to protocol treatment. Conclusions: The CR/ CRi in this relapsed population is encouraging. We plan to evaluate the efficacy of this regimen in higher-risk patients. Clinical trial information: NCT00840177." @default.
• W2953214030 created "2019-06-27" @default.
• W2953214030 creator A5011060058 @default.
• W2953214030 creator A5018065917 @default.
• W2953214030 creator A5028772063 @default.
• W2953214030 creator A5050556099 @default.
• W2953214030 creator A5055740968 @default.
• W2953214030 creator A5056405520 @default.
• W2953214030 creator A5057358612 @default.
• W2953214030 creator A5061732223 @default.
• W2953214030 creator A5066001318 @default.
• W2953214030 creator A5082944296 @default.
• W2953214030 date "2013-05-20" @default.
• W2953214030 modified "2023-10-02" @default.
• W2953214030 title "SWOG S0919: A phase II study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukemia (AML)." @default.
• W2953214030 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.7028" @default.
• W2953214030 hasPublicationYear "2013" @default.
• W2953214030 type Work @default.
• W2953214030 sameAs 2953214030 @default.
• W2953214030 citedByCount "0" @default.
• W2953214030 crossrefType "journal-article" @default.
• W2953214030 hasAuthorship W2953214030A5011060058 @default.
• W2953214030 hasAuthorship W2953214030A5018065917 @default.
• W2953214030 hasAuthorship W2953214030A5028772063 @default.
• W2953214030 hasAuthorship W2953214030A5050556099 @default.
• W2953214030 hasAuthorship W2953214030A5055740968 @default.
• W2953214030 hasAuthorship W2953214030A5056405520 @default.
• W2953214030 hasAuthorship W2953214030A5057358612 @default.
• W2953214030 hasAuthorship W2953214030A5061732223 @default.
• W2953214030 hasAuthorship W2953214030A5066001318 @default.
• W2953214030 hasAuthorship W2953214030A5082944296 @default.
• W2953214030 hasConcept C126322002 @default.
• W2953214030 hasConcept C143998085 @default.
• W2953214030 hasConcept C2778041864 @default.
• W2953214030 hasConcept C2778163477 @default.
• W2953214030 hasConcept C2778461978 @default.
• W2953214030 hasConcept C2778729363 @default.
• W2953214030 hasConcept C2779117419 @default.
• W2953214030 hasConcept C2779519902 @default.
• W2953214030 hasConcept C71924100 @default.
• W2953214030 hasConceptScore W2953214030C126322002 @default.
• W2953214030 hasConceptScore W2953214030C143998085 @default.
• W2953214030 hasConceptScore W2953214030C2778041864 @default.
• W2953214030 hasConceptScore W2953214030C2778163477 @default.
• W2953214030 hasConceptScore W2953214030C2778461978 @default.
• W2953214030 hasConceptScore W2953214030C2778729363 @default.
• W2953214030 hasConceptScore W2953214030C2779117419 @default.
• W2953214030 hasConceptScore W2953214030C2779519902 @default.
• W2953214030 hasConceptScore W2953214030C71924100 @default.
• W2953214030 hasLocation W29532140301 @default.
• W2953214030 hasOpenAccess W2953214030 @default.
• W2953214030 hasPrimaryLocation W29532140301 @default.
• W2953214030 hasRelatedWork W1983994230 @default.
• W2953214030 hasRelatedWork W2227661629 @default.
• W2953214030 hasRelatedWork W2246320611 @default.
• W2953214030 hasRelatedWork W2276111012 @default.
• W2953214030 hasRelatedWork W2299562055 @default.
• W2953214030 hasRelatedWork W2528786090 @default.
• W2953214030 hasRelatedWork W2569742291 @default.
• W2953214030 hasRelatedWork W2586994855 @default.
• W2953214030 hasRelatedWork W2591000412 @default.
• W2953214030 hasRelatedWork W2591404117 @default.
• W2953214030 hasRelatedWork W2751306657 @default.
• W2953214030 hasRelatedWork W2789948914 @default.
• W2953214030 hasRelatedWork W2922692686 @default.
• W2953214030 hasRelatedWork W2947052124 @default.
• W2953214030 hasRelatedWork W2949952334 @default.
• W2953214030 hasRelatedWork W2973031777 @default.
• W2953214030 hasRelatedWork W3097024202 @default.
• W2953214030 hasRelatedWork W3159017683 @default.
• W2953214030 hasRelatedWork W3207722841 @default.
• W2953214030 hasRelatedWork W1926806443 @default.
• W2953214030 isParatext "false" @default.
• W2953214030 isRetracted "false" @default.
• W2953214030 magId "2953214030" @default.
• W2953214030 workType "article" @default.